In this issue:
- Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma
- Incidence, mortality and survival of MCC
- Nivolumab-tacrolimusprednisone ± ipilimumab for kidney transplant recipients with cutaneous cancers
- Topical treatment of cutaneous SCC in situ
- Predicting survival in patients with stage II melanoma
- Full-body skin examination in cutaneous malignancy screening
- Dose escalation of personalised peptide-based neoantigen vaccine for metastatic melanoma
- Association between dermatology follow-up and melanoma survival
- Extended-dosing cemiplimab in advanced cutaneous SCC
- SLNB unreliable for predicting melanoma mortality regardless of age
Please login below to download this issue (PDF)